Chicago, March 14, 2024–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered cardiovascular precision medicine company, announced that it will showcase its breakthrough HeartRisk.^TM Actionable clinical intelligence^TM will present the platform at the American College of Cardiology’s 73rd Annual Scientific Sessions (ACC.24), April 6-8, 2024 in Atlanta, Georgia. Cardio Diagnostics’ mission aligns with this year’s ACC.24 conference theme, “Progress.” Cardiovascular care for everyone. ” By leveraging cutting-edge technology at the intersection of genomics, epigenomics and artificial intelligence, we are advancing precision medicine in cardiology and raising the bar of cardiovascular care available to patients.

Innovations on display at ACC.24

All attendees, including providers, provider organizations, and potential industry partners, are welcome to learn more about Cardio Diagnostics’ HeartRisk and actionable clinical intelligence platform at booth 3605. The booth will feature live demonstrations and informative presentations that delve into HeartRisk’s features and benefits. Actionable Clinical Intelligence V.3 provides hands-on experience with these innovative technologies.

Heart risks: HeartRisk is a cardiovascular risk intelligence platform customized to provide actionable insights to at-risk provider organizations and value-based cardiology groups to identify and stratify at-risk populations and identify contributing factors. By understanding the , you can better manage shared risk and value-based contracts. Reduce your risk of heart disease and ensure quality assessments and evaluations are met. HeartRisk gives organizations new tools to manage cardiovascular disease in patient populations at scale while supporting cost containment efforts and realizing the value of risk-based contracting. .

Practical Clinical Intelligence V.3: Building on the success of the previous version, which premiered at ACC in 2023, Actionable Clinical Intelligence V.3 takes precision medicine to new heights. Actionable Clinical Intelligence (ACI) is integrated with Cardio Diagnostics’ clinical blood tests, Epi+Gen CHD and PrecisionCHD, to provide healthcare providers with deeper, actionable insights into the drivers of coronary heart disease in their patients. To do. At the heart of ACI is the ability for healthcare providers to measure the impact of lifestyle and therapeutic interventions on underlying heart disease. Healthcare providers who are now able to better understand and monitor changes in heart attack risk and the progression of coronary heart disease due to ACI will be better able to develop individualized and dynamic prevention and treatment strategies for their patients. You will be able to implement it properly.

story continues

Meesha Dogan Ph.D., CEO and co-founder of Cardio Diagnostics, said: “Our new innovative solutions, HeartRisk and Actionable Clinical Intelligence V.3, have the potential to revolutionize the way healthcare professionals approach the prevention, detection, and management of cardiovascular disease. We look forward to working with the company to demonstrate how our technology can make a meaningful difference in cardiovascular disease.” We drive value for our partners and strategic partners. ”

engage with us

The company’s leadership team will be on-site to discuss how Cardio Diagnostics’ solutions can be seamlessly integrated into clinical settings to improve patient outcomes and streamline treatment processes. Additionally, in advance of the April 4, 2024 conference, we will host an intimate, invitation-only networking event connecting healthcare leaders from his Vizient member organizations. If you are interested in participating, please email support@cardiodiagnosticsinc.com. Attendees will have the opportunity to discuss how their organizations are rethinking cardiovascular care and the role of innovation and precision medicine converging to improve patient health and outcomes.

About heart diagnosis

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and accurate. The Company is a leading medical technology company leveraging its unique artificial intelligence (AI)-driven integrated gene-epigenetic engine for cardiovascular diseases (the “Core Technology”) to further develop and commercialize clinical tests to improve prevention and detection. It was established to become one of the companies. , treatment of cardiovascular diseases. For more information, please visit www.cardiodiagnosticsinc.com.

Forward-looking statements

Certain statements and information contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words and phrases “will,” “likely to result,” and “anticipated” are used. “…”, “continue”, “anticipate”, “estimate”, “anticipate”, “intend”, “goal” or similar expressions mean “future” within the meaning of Private Securities Litigation Reform. The objective is to identify “forward-looking statements”. 1995 Act. Such statements are subject to certain risks and uncertainties, known and unknown, many of which are beyond our control. Such uncertainties and risks include our ability to successfully execute our growth strategy, changes in laws and regulations, economic conditions, dependence on management, shareholder dilution, capital shortages and rapid growth. including, but not limited to, the impact on our company and other factors. Financing our management’s ability to effectively respond to growth and demand on our products and services, newly developed technologies, our ability to compete, regulatory matters, technology protection, the effects of competition and our future acquired capabilities; An extensive list of factors that may affect future results is included in our Form 10-K for the periods ended December 31, 2022, and March 31, 2023 and September 30, 2023. Current Report on Form 10-Q for the period discussed. Part I, Item IA under the heading “Risk Factors” and other documents filed from time to time with the Securities and Exchange Commission. Such factors could have a material adverse effect on our financial results and could cause our actual results in future periods to differ materially from the opinions and statements expressed in this press release. There is a gender.

View source version on businesswire.com. https://www.businesswire.com/news/home/20240314714610/ja/

contact address

Investor:
Gene Mannheimer
PR for investors
855-226-9991
investors@cardiodiagnosticsinc.com

Media and public relations:
Quran Abdullahi
855-226-9991
pr@cardiodiagnosticsinc.com